Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse. Case Presentation: A 47-year-old female with medical history of stage IV follicular n...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-09-01
|
| Series: | GE: Portuguese Journal of Gastroenterology |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/533499 |